SCHEMBL6704746

SCHEMBL6704746

CC(=O)c1cccc(-c2ccc(O[Si](C)(C)C(C)(C)C)c(C34CC5CC(CC(C5)C3)C4)c2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.46
RARA P10276 7/20 0.46
RARB P10826 5/20 0.46
RARG P13631 5/20 0.46
PGR P06401 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
NR1I2 O75469 1/20 0.46
LMNA P02545 1/20 0.46
HSPD1 P10809 1/20 0.46
GOT1 P17174 1/20 0.46
GLRA1 P23415 1/20 0.46
BLM P54132 1/20 0.46
HSPE1 P61604 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
HDAC11 Q96DB2 4/20 0.42
HDAC2 Q92769 1/20 0.42
IKBKB O14920 4/20 0.42
HDAC1 Q13547 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7687188 0.88 RARA (0.47) RARARARBRARGPGRMEN1
SCHEMBL6618558 0.82 HDAC11 (0.42) FAAHRARARARBRARGPGR
SCHEMBL6706257 0.82 RARB (0.39) FAAHRARARARBRARGPGR
SCHEMBL6622319 0.81 RARB (0.39) FAAHRARARARBRARGPGR
SCHEMBL981497 0.81 RARG (0.72) RARARARBRARGPGRMEN1
SCHEMBL6621729 0.81 HDAC11 (0.39) FAAHRARARARBRARGPGR
SCHEMBL9130746 0.79 RARA (0.45) RARARARBRARGPGRMEN1
SCHEMBL8458638 0.79 RARG (0.55) RARARARBRARGPGRMEN1
SCHEMBL8461452 0.79 RARA (0.45) RARARARBRARGPGRMEN1
SCHEMBL7077371 0.79 RARB (0.61) RARARARBRARGPGRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040097566-A1 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer INCYTE SAN DIEGO INCORPORATED 2004-05-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097566-A1 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer PTPA, PTPRC, PTPRCAP FAAH 3299/4885RARA 2825/4885RARB 2680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.